Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.55 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL28366079 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL28366077 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL626780 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2069640 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21647170 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL22320723 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL3978613 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20492652 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL22320722 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL29635022 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661866-A1 | PSILOCIN FORMULATIONS | Eleusis Therapeutics US, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024166029-A1 | PSILOCIN FORMULATIONS | ELEUSIS THERAPEUTICS US, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| US-9610293-B2 | Co-micronization product comprising ulipristal acetate | LABORATOIRE HRA-PHARMA (FR) | 2017-04-04 | — | — | US | claimed |
| EP-1912667-B1 | CONCENTRATED PROTEIN LYOPHILATES, METHODS, AND USES | AMGEN INC (US) | 2012-08-29 | — | — | EP | claimed |
| US-7956160-B2 | Freeze dried protein composition comprising manitol polymorphs which reconstitute quickly upon addition of diluent and provide solutions of high protein concentrations, with reduced formation of foam, effervescence, bubbles, aggregates and particulates | AMGEN INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-1912667-A4 | CONCENTRATED PROTEIN LYOPHILATES, METHODS, AND USES | AMGEN INC (US) | 2009-05-13 | — | — | EP | claimed |
| US-20080213215-A1 | Concentrated Protein Lyophilates, Methods, and Uses | AMGEN INC. | 2008-09-04 | — | — | US | claimed |
| EP-1912667-A2 | CONCENTRATED PROTEIN LYOPHILATES, METHODS, AND USES | Amgen, Inc (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007014073-A2 | CONCENTRATED PROTEIN LYOPHILATES, METHODS, AND USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | claimed |
| US-20260097113-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING AN RSV F PROTEIN TRIMER | PFIZER (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4661866-A1 | PSILOCIN FORMULATIONS | Eleusis Therapeutics US, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| WO-2025245024-A1 | COMPOSITIONS COMPRISING LIOTHYRONINE AND METHODS OF MAKING THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2005061088-A1 | POWDER FORMATION BY ATMOSPHERIC SPRAY-FREEZE DRYING | FINLAY WARREN H (CA) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005025499-A2 | HYDROPHOBIC DRUG COMPOSITIONS CONTAINING RECONSTITUTION ENHANCER | CELL THERAPEUTICS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004090446-A1 | METHOD AND APPARATUS FOR FREEZE DRYING MATERIAL | ACTON ELIZABETH (GB) | 2004-10-21 | — | — | WO | disclosed |
| EP-0538858-B1 | Improved lyophilized ifosfamide compositions | BRISTOL MYERS SQUIBB CO (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5227373-A | 3-/Chloroethyl/-2-/chloroethylamino/tetrahydrophosphorin-oxide and urea excipient in water are frozen, and water is removed by sublimation; improved heat stability and shelf-life; dosage unit formulation | BRISTOL-MYERS SQUIBB CO. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0538858-A1 | Improved lyophilized ifosfamide compositions | Bristol-Myers Squibb Company (US) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | PDE4A 1913/4885TOP1 1927/4885LMNA 3478/4885 |
| US-20260097113-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING AN RSV F PROTEIN TRIMER | MAX, FURIN, SET | PDE4A 4236/4885TOP1 4695/4885LMNA 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.